FGFarshad Gharebakhshi

Farshad Gharebakhshi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Farshad Gharebakhshi has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of SGLT2 inhibitors on kidney stones; a systematic review and meta-analysis

    by Ali Rahnama Sisakht, Parvin Kamkar, Mohammad Mehdi Darzi, Mohammad Hamidi Madani, Rasoul Jafari Arismani, Farshad Gharebakhshi, Mahdi Behi, Hossein Mardanparvar, Ramin Haghighi

    Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are among the antidiabetic drugs with unclear relationship effect on kidney stones. Accordingly, this study aimed to investigate the relationship between SGLT2 inhibitors treatment and kidney calculi incidence using systematic review and meta-analysis. Materials and Methods: The PRISMA statement was used to write this systematic review and meta-analysis. Databases, including ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar, were used to access the resources without a lower time limit until November 5, 2023. Data analysis was conducted using STATA 14 software. Results: Results obtained from six studies with a total of 4963542 participants indicated that SGLT2 inhibitors administration reduced the possibility of kidney calculi in general (OR = 0.80, 95% CI: 0.72, 0.89), in men (OR = 0.92, 95% CI: 0.86, 0.98), and women (OR = 0.93, 95% CI: 0.89, 0.97). SGLT2 inhibitors treatment prevented kidney calculi in cross-sectional studies (OR = 0.92, 95% CI: 0.89, 0.96), cohort studies (OR = 0.71, 95% CI: 0.66, 0.77), RCT study (OR = 0.64, 95% CI: 0.48, 0.86), Japan (OR = 0.92, 95% CI: 0.89, 0.96), United States (OR = 0.72, 95% CI: 0.67, 0.76), Denmark (OR = 0.51, 95% CI: 0.37, 0.71), compared with DPP4i (OR = 0.74, 95% CI: 0.71, 0.77), compared with GLP1RA (OR = 0.62, 95% CI: 0.47, 0.82), compared with other antidiabetic drugs (OR = 0.92, 95% CI: 0.89, 0.96), and compared with placebo (OR = 0.64, 95% CI: 0.48, 0.86). Conclusion: Compared with placebo and other antidiabetic drugs, SGLT2 inhibitors reduce the risk of kidney calculi. However, considering the limited number of investigated studies, more studies in this field are required. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023483132) and Research Registry (UIN: reviewregistry1743) websites.


  • Open Access

    Association between vitamin D and bladder neoplasm; a systematic review and meta-analysis

    by Anna Ghorbani Doshantapeh, Mohammad Hamidi Madani, Ali Khodaparast, Rasoul Jafari Arismani, Ardeshir Matoofi, Delnia Heidari, Golmis Abdolmohammadi, Farshad Gharebakhshi, Jahanbakhsh Vahdatnejad

    Introduction: Bladder neoplasm ranks as the second most prevalent reproductive system malignancy worldwide. On the other hand, the vitamin D as an anti-cancer agent has been a subject of long-standing speculation. Hence, the objective of this study is to explore the correlation between vitamin D and bladder neoplasm risk. Materials and Methods: This systematic review and meta-analysis were designed following the PRISMA checklist. Eligible studies were identified through searches on ProQuest, PubMed, Web of Science, Google Scholar, and Cochrane, with no time restrictions until November 18, 2023. Data analysis was conducted utilizing the STATA 14 software. Results: Serum vitamin D levels less than 50 nmol/L increased the risk of bladder neoplasm (OR: 1.33; 95% CI: 1.08, 1.64), muscle-invasive bladder cancer (MIBC) (OR: 2.73; 95% CI: 1.80, 4.14) and non-muscle invasive bladder cancer (NMIBC) (OR: 1.87 (95% CI: 1.39, 2.52)). However, the risk of bladder neoplasm in people whose serum vitamin D level was less than 50 nmol/L did not increase with age. Vitamin D serum levels greater than or equal to 50 nmol/L in people aged 40 to 49 (OR: 0.51; 95% CI: 0.27, 0.99) prevented bladder neoplasm, but no significant association was seen in people over 50 years old. In addition, there was no significant association between daily vitamin D intake and the risk of bladder neoplasm (OR: 1.13; 95% CI: 0.63, 2.06). Conclusion: The serum vitamin D less than 50 nmol/L was correlated with bladder cancer risk increasing, including MIBC and NMIBC. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023487519) and Research Registry (UIN: reviewregistry1754) Websites.


  • Open Access

    The association between metformin administration and non-Hodgkin lymphoma; a systematic review and meta-analysis of cohort and case-control studies

    by Elnaz Ataei, Razieh Bagheri Shahzadeh Aliakbari, Navid Asgari, Nasim Zaman Samghabadi, Sina Salati, Sara Abbasian, Mohammad Akbari, Farshad Gharebakhshi, Anna Ghorbani Doshantapeh

    Introduction: Metformin, a blood sugar-lowering agent, has the potential to be an anti-cancer agent. However, its role in lymphoma remains uncertain. Objectives: This study sought to examine the correlation between the utilization of metformin and non-Hodgkin lymphoma through the application of a systematic review and meta-analysis methodology. Materials and Methods: This investigation was carried out in the form of a methodical examination and meta-analysis in accordance with the PRISMA guidelines. Databases such as Scopus, PubMed, Web of Science, Cochrane, and the Google Scholar search engine were thoroughly explored without any temporal limitations until September 20, 2023. The data was analyzed utilizing the STATA 14 software, and the level of significance for the tests was established at P<0.05. Results: The results, obtained by combining six observational studies (five cohort studies and one case-control study) with a total sample size of 2 330 787 individuals, showed that the odds ratio (OR) for the association between metformin use and non-Hodgkin lymphoma in all studies was 0.91 (95% CI: 0.78, 1.07). In cohort studies, the OR was 0.91 (95% CI: 0.74, 1.11), and in the case-control study, it was 0.93 (95% CI: 0.79, 1.10). None of these relationships were statistically significant. The odds ratio between metformin uses and chronic lymphocytic leukemia/small lymphocytic leukemia was 0.93 (95% CI: 0.71, 1.21), and the odds ratio between metformin use and diffuse large B-cell lymphoma was 1.06 (95% CI: 0.61, 1.83), both of which were not statistically significant. Conclusion: This investigation’s findings indicated no statistically noteworthy correlation exists between the utilization of metformin and the probability of contracting non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic leukemia, and diffuse large B-cell lymphoma. Registration: This study was conducted following the PRISMA checklist. Its protocol was registered on the PROSPERO (CRD42023469100) and Research Registry (UIN: reviewregistry1721) websites.


  • Prognostic Clinical Phenotypes of Patients with Acute Decompensated Heart Failure

    by Tanya Mohammadi, Said Tofighi, Babak Mohammadi, Shadi Halimi, Farshad Gharebakhshi

    Introduction Acute decompensated heart failure (AHF) is a clinical syndrome with a poor prognosis. Aim This study was conducted to identify clusters of inpatients with acute decompensated heart failure that shared similarities in their clinical features. Methods We analyzed data from a cohort of patients with acute decompensated heart failure hospitalized between February 2013 and January 2017 in a Department of Cardiology. Patients were clustered using factorial analysis of mixed data. The clusters (phenotypes) were then compared using log-rank tests and profiled using a logistic model. In total, 458 patients (255; 55.7% male) with a mean (SD) age of 72.7 (11.1) years were included in the analytic dataset. The demographic, clinical, and laboratory features were included in the cluster analysis. Results The two clusters were significantly different in terms of time to mortality and re-hospitalization (all P < 0.001). Cluster profiling yielded an accurate discriminating model (AUC = 0.934). Typically, high-risk patients were elderly females with a lower estimated glomerular filtration rate and hemoglobin on admission compared to the low-risk phenotype. Moreover, the high-risk phenotype had a higher likelihood of diabetes type 2, transient ischemic attack/cerebrovascular accident, previous heart failure or ischemic heart disease, and a higher serum potassium concentration on admission. Patients with the high-risk phenotype were of higher New York Heart Association functional classes and more positive in their medication history. Conclusions There are two phenotypes among patients with decompensated heart failure, high-risk and low-risk for mortality and re-hospitalization. They can be distinguished by easy-to-measure patients’ characteristics.


  • Open Access

    The effect of cinacalcet on hypercalcemia in kidney transplant patients with hyperparathyroidism: systematic review and meta-analysis

    by Hanie Fooladi, Fatemeh Vashahi Torfi, Ali Khodaparast, Sara Abbasian, Noorbakhsh Alivand, Mohamad Khaledi, Soleyman Alivand, Farshad Gharebakhshi, Moein Shakerian

    Introduction: Following renal transplantation, patients with end-stage renal disease develop parathyroid dysfunction and electrolyte abnormalities, including calcium and phosphate levels. However, cinacalcet is one of the most used medications for hypercalcemia. Therefore, the present systematic review and meta-analysis aimed to investigate the effect of cinacalcet administration on hypercalcemia in patients with renal transplantation. Materials and Methods: The online databases of Cochrane, Web of Science, Scopus, and PubMed were searched until April 2023 using validated keywords. Moreover, PRISMA was used for qualitatively evaluating the studies since the study protocol was registered on the PROSPERO website. In addition, data analysis was conducted using Stata version 14, and the significance level was set at 0.05. Results: The present meta-analysis included 26 studies (24 cohort studies and two randomized clinical trials) investigating 602 patients with renal transplantation and hyperparathyroidism. According to our findings, cinacalcet reduced the serum calcium (MD: -2.24, 95% CI: -2.82, -1.67), parathormone (SMD: -0.85, 95% CI: -1.15, -0.54), and alkaline phosphatase levels (SMD: -0.45, 95% CI: -0.91, -0.01). Moreover, 30-60 mg of cinacalcet per day effectively treated hypercalcemia (SMD: -2.77, 95% CI: -3.57, -1.98), while other doses were not significantly effective. Furthermore, the effect of cinacalcet was investigated in patients using the medication for less than six months (SMD: -2.55, 95% CI: -4.25, -0.86), 12-18 months (SMD: -2.60, 95% CI: -3.53, -1.67), and more than 24 months (SMD: -1.71, 95% CI: -2.54, -0.88). Finally, the effect of cinacalcet was the highest in the patients who were 60-64 years old compared to other age groups (SMD: -3.59, 95% CI: -5.14, -2.04). Conclusion: Cinacalcet could improve hypercalcemia and hyperparathyroidism in patients with renal transplantation. Moreover, the effect of cinacalcet had a direct and positive relationship with the patient’s age. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42023428620) and Research Registry (UIN: reviewregistry1667) website.

  • Open Access

    Dapagliflozin in patients with chronic kidney disease: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled multicenter trials

    by Hamidreza Khodabandeh, Hanieh Molaee, Ladan Ghashghaie, Mohammad Reza Farnia, Soleyman Alivand, Faraz Zandiyeh, Farshad Gharebakhshi, Elham Rashidi, Nahid Mir

    Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce the mortality rate, hospitalization, and cardiac morbidity in diabetic patients. However, their safety in chronic kidney disease (CKD) individuals is still debatable. Objectives: The present study aims to evaluate the effect of dapagliflozin on primary composite outcomes and mortality rate in CKD patients using a systematic review and meta-analysis approach. Materials and Methods: In this meta-analysis, Cochrane, Web of Science, Scopus, and PubMed databases, along with the Google Scholar search engine, were queried until March 2023. Data were analyzed by STATA software version 14 at a significance level of P<0.05. Results: A total of nine randomized clinical trials (RCTs) articles were reviewed, with a sample size of 16720 in the dapagliflozin group and 13 476 in the placebo group. Dapagliflozin use (10 mg/d) compared to placebo improved primary composite outcomes in CKD patients by 39% (OR=0.61, 95% CI: 0.57, 0.65) while reducing the mortality rate by 31% (OR=0.69, 95% CI: 0.63, 0.76). In an analysis by treatment length, no statistically significant change was noted in early composite outcomes (OR=0.70, 95% CI: 0.48, 1.01) and mortality rate (OR=0.75, 95% CI: 0.39, 1.45) between patients who were on dapagliflozin for less than two years and the placebo group. However, patients receiving dapagliflozin for two years and above had significantly improved primary composite outcomes (OR=0.60, 95% CI: 0.55, 0.66) and mortality rate (OR=0.69, 95% CI: 0.61, 0.79) compared to the placebo group. Conclusion: Dapagliflozin use, compared to placebo, improved the early composite outcomes and mortality rate in CKD patients. Prescribing a daily dose of 10 mg for a treatment duration of over two years seems safe in these patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023422186).


  • Open Access

    Prevalence and predicting factors of acute kidney injury due to methanol intoxication; a systematic review

    by Mohammad Hesam Gharaeikhezri, Farinaz Fattahi, Pegah Karami, Arash Izadpanah Ghahremani, Bareza Rezaei, Hooman Rafiei, Hamidreza Khodabandeh, Aisan Ghasemi Oskui, Farshad Gharebakhshi, Mohammad Reza Rezaei

    Introduction: Methanol intoxication and subsequence acute kidney injury (AKI) can be dangerous and deadly in case of a missed or delayed diagnosis; therefore, identifying its prevalence and predictor factors is necessary. Objectives: This study was conducted to identify the prevalence and predictor factors of AKI in methyl alcohol-intoxicated patients. Methods and Materials: The search strategy was conducted with the standard keyword in the international database, including Web of Science, Scopus, PubMed /Medline, Embase, Cochrane, WorldCat, Dimension, OpenGrey, EBSCO, DOAJ, CINAHL, and Google scholar search engines. Studies that reported the prevalence of AKI due to methanol poisoning were included in this review study. Results: Results demonstrated that six studies from five countries, with a sample size of 816 methanol intoxication patients, were included in this study. Mean AKI prevalence in all reviewed studies was 28.18%; Gender male, hypertension, older age, anemia, alcohol addiction, metabolic acidosis, high blood osmolality, high Formate concentration, alcohol overdose, sepsis, rhabdomyolysis, acute pancreatitis, and volume depletion were the reported AKI predictors in the reviewed studies. Conclusion: Identifying the AKI prevalence and its predictor factors in patients with methanol intoxication can help in their quick diagnosis, timely treatment, and reduce the subsequent complications.


  • Open Access

    Immunity due to COVID-19 vaccination and its correlation with lung involvement severity as an indicator of disease severity

    by Razieh Mousapour, Mostafa Assarroudi, Yaser Khanchemehr, Masoomeh Mehrbarjou, Golmis Abdolmohammadi, Farshad Gharebakhshi, Erfan Ghanbarzadeh, Hussein Soleimantabar

    Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is a worldwide challenge; regarding the lack of an effective and efficient drug. It seems that the vaccine is the only modality to save the world from this pandemic. Objectives: This study was conducted to assess the effect of vaccination on preventing pulmonary involvement and the disease severity of COVID-19 patients. Patients and Methods: This descriptive-analytical study was conducted on 247 people with coronavirus disease 2019 infection. Demographic characteristics and vaccination status information were collected. Patients’ lung computed tomography scan findings were scored based on the pulmonary involvement percentage, and then according to this score, they were graded into severe, moderate, mild, and without lung involvement. The association between pulmonary involvement and vaccination status were evaluated by Fisher’s exact test and logistic regression. Results: Most participants were male, with a mean age of 53.74 ± 10.96 years. Most people (42.9%) were partial-vaccinated. Lungs in 53.3% were with lung involvement and in 46.6% were without. The correlation between pulmonary involvement and vaccination was significant (P<0.001). Conclusion: Vaccination is an effective and efficient method in preventing coronavirus disease 2019 severity.

  • Open Access

    The association between hyperuricemia and the risk of acute kidney injury; a systematic review and meta-analysis

    by Mohammad Reza Rezaei, Mohamad Khaledi, Bareza Rezaei, Mohammad Reza Farnia, Hooman Rafiei, Samira Moradi, Pegah Karami, Farshad Gharebakhshi, Farinaz Fattahi

    Introduction: Acute kidney injury (AKI) is a prevalent clinical syndrome in hospitalized patients associated with uric acid levels in patients. This study aims to evaluate the relationship between hyperuricemia and the risk of AKI using a systematic review and meta-analysis approach. Materials and Methods: This systematic review and meta-analysis was performed based on PRISMA guidelines. A query on international databases, including Cochrane, Web of Science, PubMed, Scopus, and the Google Scholar search engine, was conducted using relevant keywords. The literature search stage was updated until January 2023. Data were analyzed in STATA 14 software. A significance level of P < 0.05 was considered for all tests. Results: A total of 22 articles published from 2006 to 2023 with a sample size of 82469 patients were reviewed. The estimated odds ratio (OR) was 1.96 (95% CI: 1.63, 2.35, P=0.000, I2=89.6%) between hyperuricemia and the risk of AKI and 1.64 (OR: 1.64; 95% CI: 1.23, 2.20, P=0.012, I2=63.2%) between hyperuricemia and AKI mortality and these relationships were statistically significant. In addition, the OR of hyperuricemia and AKI was 1.96 (95% CI: 0.97, 3.98, P=0.000, I2=97.9%) in males and 2.34 (OR: 2.34; 95% CI: 1.14, 4.78, P=0.000, I2=97.9%) in females. The OR of hyperuricemia and AKI was 1.07 (95% CI: 1.03, 1.10) in 30-39 years, 2.37 (95% CI: 1.04, 5.42) in 40-49 years, 4.71 (95% CI: 1.29, 17.20) in 50-59 years, 2.07 (95% CI: 1.58, 2.71) in 60-69 years, and 1.42 (95% CI: 1.04, 1.93) in 70-79 years age groups. Conclusion: Hyperuricemia significantly increases the risk of AKI and mortality. Therefore, by reducing the serum level of uric acid, the risks caused by it can be avoided. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023393648).

  • Open Access

    The effects of atorvastatin on contrast-induced acute kidney injury; a systematic review and meta-analysis on clinical trials

    by Kianoush Saberi, Ali Rahnama Sisakht, Ghasem Sobhani, Faraz Zandiyeh, Mohammad Sadegh Golvardi Yazdi, Saeed Soltanizadeh, Sara Rasta, Farshad Gharebakhshi, Mohamad Khaledi

    Introduction: Contrast-induced acute kidney injury (CI-AKI) is a major acute renal failure that can be prevented by atorvastatin administration. This study aims to evaluate the association between atorvastatin use and CI-AKI incidence using a systematic review and meta-analysis approach. Materials and Methods: Several international databases, including Cochrane, Web of Science, Scopus, ProQuest, PubMed, and the Google Scholar search engine, were queried in this study. STATA 14 software was conducted to analyze the data. In this study, standardized mean difference (SMD) index was conducted to investigate the relationship between atorvastatin and serum creatinine level. Results: Twelve clinical trials with a total sample size of 3299 were retrieved. The effect of atorvastatin on serum creatinine levels indicated a SMD of -2.26 (95% CI: -2.53, -1.98) at a dose of 20 mg/kg, -0.76 (95% CI: -1.47, -0.05) at a dose of 40 mg/kg, -2.69 (95% CI: -2.96, -2.42) at a dose of 60 mg/ kg, and -0.03 (95% CI: -0.14, 0.09) at a dose of 80 mg/kg. The effect of atorvastatin use on serum creatinine levels achieved a SMD of -2.72 (95% CI: -3.02, -2.43) in the 40-49 years age group and a SMD of -0.96 (95% CI: -1.73, -0.19) in the 50-59 years age group. The effect of high-dose atorvastatin therapy in reducing the serum creatinine levels, compared to low-dose therapy, was a SMD of -0.54 (95% CI: -1.03, -0.04). However, estimates for the effect of atorvastatin compared to rosuvastatin and placebo showed a SMD of -0.26 (95% CI: -0.76, 0.24) and -1.23 (95% CI: -2.22, -0.25), respectively. The effect of atorvastatin on blood urea nitrogen (BUN) and high-sensitivity C-reactive protein (hs-CRP) levels relative to the comparison group was a SMD of -1.10 (95% CI: -1.61, -0.58) and -1.36 (95% CI: -2.30, -0.42) respectively. Conclusion: Pre-treatment with atorvastatin is effective in CI-AKI prevention. High-dose atorvastatin administration at younger ages provides the best outcome for preventing CI-AKI. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023397276, available at https:// www.crd.york.ac.uk/prospero/#recordDetails).